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ABSTRACT
A growing number of studies support that the bidirectional interactions between the gut micro-
biota, the immune system and the CNS are relevant for the pathophysiology of MS. Several studies 
have reported alterations in the gut microbiome of MS patients. In addition, a variety of studies in 
animal models of MS have suggested that specific members of the gut commensal microbiota can 
exacerbate or ameliorate neuroinflammation. Probiotics represent oral nontoxic immunomodula-
tory agents that would exert benefits when using in combination with current MS therapy. Here we 
investigate the effect of Vivomixx on the gut microbiome and central and peripheral immune 
responses in a murine model of primary progressive MS. Vivomixx administration was associated 
with increased abundance of many taxa such as Bacteroidetes, Actinobacteria, Tenericutes and TM7. 
This was accompanied by a clear improvement of the motor disability of Theiler’s virus infected 
mice; in the CNS Vivomixx reduced microgliosis, astrogliosis and leukocyte infiltration. Notably, the 
presence of Breg cells (CD19+CD5+CD1dhigh) in the CNS was enhanced by Vivomixx, and while 
spinal cord gene expression of IL-1β and IL-6 was diminished, the probiotic promoted IL-10 gene 
expression. One of the most significant findings was the increased plasma levels of butyrate and 
acetate levels in TMEV-mice that received Vivomixx. Peripheral immunological changes were subtle 
but interestingly, the probiotic restricted IL-17 production by Th17-polarized CD4+ T-cells purified 
from the mesenteric lymph nodes of Theiler’s virus infected mice. Our data reinforce the beneficial 
effects of oral probiotics that would be coadjuvant treatments to current MS therapies.
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Introduction
Although the etiology of MS remains unknown, envir-
onmental and genetic risk factors are involved in the 
pathogenesis of the disease.1 Accumulating evidence 
indicate that microbiome gut dysbiosis may be impli-
cated in the increased incidence of MS in developed 
countries.2 Specifically, bi-directional interactions 
between the gut microbiota, the intestinal barrier 
and the immune system appear to be relevant to the 
pathophysiology of MS.3–5 The different stages and 
subtypes of MS are influenced by environmental 
factors,1 particularly in the relapsing remitting MS 
forms (RRMS) with current successful therapies. 
Studies using the encephalomyelitis autoimmune 
experimental (EAE) model of MS described lower 
incidence in germ free (GF) or antibiotic treated 
mice than in specific pathogen free (SPF) mice,6–8 
while recolonization restored the susceptibility to 
develop EAE.3 However, other studies reported 
a therapeutic role of probiotic administration in 
a variety of EAE models. On this matter, orally admin-
istration of Bacteroides fragilis,9,10 Prevotella 
histicola,11 different species of Lactobacillus 
(L. paracasei plus L. plantarum;12 L. Reuteri;13 
L. helveticus14), or multi-strain probiotics15 have 
demonstrated to improve EAE. In addition, probiotics 
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supplementation to RRMS patients has been shown to 
modulate immunity by exerting anti-inflammatory 
effects.16,17
Right now, there is little information regard-
ing the association between gut microbes and 
CNS inflammation/neurodegeneration in the 
primary progressive MS. Notably, MRI studies 
in progressive MS show less brain permeability, 
probably reflecting CNS compartmentalized 
inflammation. As a result, we have studied the 
effect of administering the oral multi-strain 
probiotic, Vivomixx, on the gut microbiome 
and plasma short chain fatty acids (SCFAs) in 
the late chronic phase of a murine model of 
PPMS, the Theiler’s murine encephalomyelitis 
virus induced demyelinating disease (TMEV- 
IDD).
Results
Vivomixx treatment on the symptomatic chronic 
phase of TMEV-IDD improves motor function
We explored the effect of manipulating the gut 
microbiota by oral administration of Vivomixx dur-
ing the chronic phase of disease (Figure 1(a)). 
Consumption of this probiotic improved motor 
function (Figure 1(b)), witnessed through the 
increase in the horizontal and vertical activity dis-
played by these mice (HACTV p < .01 vs TMEV- 
mice), as opposed to the more limited activity of the 
vehicle treated TMEV-mice (TMEV p < .01 vs sham 
mice). The reduced latency to fall observed in 
TMEV-mice on the rotarod performance confirmed 
the motor improvement induced by Vivomixx sup-
plementation (p < .01 vs TMEV-mice).
Figure 1. Vivomixx-treatment improves the motor disability of TMEV-mice. (a) Scheme of the experimental groups. Mice were 
administered 3 × 108 cfu Vivomixx by oral gavage three times a week from day 70 pi to 85 dpi. Control mice were administered 
autoclaved water alone. b) Horizontal (HACTV) and vertical activity (VACTV), as well as motor coordination were evaluated. The data are 
presented as the means ± SEM: ***p < .001 vs. S; ##p < .01 vs T; n = 10 mice/group studied in two independent experiments.
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Effects of oral Vivomixx on gut microbiota and 
blood content of SCFAs
Miseq Illumina analysis of the bacterial population 
revealed that TMEV-mice showed a decreased rela-
tive abundance of Bacteroides, Parabacteroides, 
Prevotella, Sutterella or Desulfovibrio while an 
increase of Anaerostipes, Dorea, 
Erysipelotrichaceae or Coprobacillus were observed 
(Figure 2(a)). Sham mice subjected to oral 
Vivomixx treatment experiment subtle changes in 
gut microbiota composition. In the case of 
Vivomixx-TMEV mice the relative abundance 
Anaerostipes, Dorea, Oscillospira, 
Enterobacteraceae or Ruminococcus were decreased 
while Bacteroides, Odoribacter, Lactobacillus, or 
Sutterella were increased (Figure 2(a)). To give 
robustness to our data we compare the gut micro-
biota composition of TMEV-mice before and after 
Vivomixx treatment, we found an increased relative 
abundance of Bacteroidetes and a significant 
decrease in Firmicutes. In addition, the percentage 
of bacteria belonging to Actinobacteria, Tenericutes 
and TM7 phyla tend to increase, but not signifi-
cantly (Figure 2(b)). At genus level (Figure 2(c)), 
Vivomixx treatment tend to rebalance microbiota 
changes increasing the relative abundance of 
Bacteroides, Odoribacter or Lactobacillus, while 
Oscillospira, Ruminococcus or Bilophila were signif-
icantly reduced. Gut microbiota changes would be 
related to the increased levels of acetate and buty-
rate observed in the plasma of TMEV-mice after 
15 days of probiotic treatment (Figure 2(d)).
Oral Vivomixx alters CNS infiltrates in the TMEV-IDD 
augmenting the frequency of the regulatory 
B220+CD19+CD5+CD1high B lymphocytes
We assessed whether administering Vivomixx altered 
the T cell subpopulation in the CNS of TMEV-mice 
(Figure 3(a)). A tendency toward a reduction in the 
proportion of CD4+ T cells was observed (Figure 3 
(b)), with no change in the frequency of CD8+ T cells 
(Figure 3(c)). However, the increase in the number of 
leukocytes in the CNS of TMEV-infected mice was 
significantly dampened by probiotic supplementation 
(Figure 3(d)). In addition, probiotic gavage did not 
significantly modify the proportions of 
Foxp3+CD39+CD4+ or Foxp3−CD39+CD4+ T cells 
in the CNS of TMEV-infected mice (Figure 3(e-g)). 
Conversely, the presence of B cells (Figure 3(h)) was 
strongly influenced by oral Vivomixx administration, 
which significantly reduced the proportion of B cells 
(Figure 3(i); p < .001 TMEV vs sham; p < .001, 
TMEV plus Vivomixx vs TMEV). More interestingly, 
Vivomixx enhanced the presence of the Breg subpo-
pulation B220+CD19+CD5+CD1dhigh cells (Figure 3 
(j); p < .05 vs TMEV).
Oral Vivomixx modifies microglial morphology and 
reduces astrogliosis promoting an 
anti-inflammatory profile in the spinal cord
Microglial cells maintain the CNS homeostasis, being 
activated in MS and its experimental models. As 
expected, the area of Iba-1 staining is larger in 
TMEV-mice (p < .01 vs sham mice) and Vivomixx 
enhanced this effect, further increasing the area of 
Iba-1 staining (p < .05 vs TMEV: Figure 4(a)). 
Nevertheless, a detailed examination of these cells 
indicated subtle morphological changes in the spinal 
cord of mice that received Vivomixx reflecting that 
microglia exhibited anti-inflammatory activation or 
attenuated proinflammatory activity (Figure 4(a)). In 
addition, probiotic supplementation was associated 
with weaker Vimentin-GFAP co-localization in the 
spinal cord of TMEV-infected mice, whereas TMEV- 
mice had a higher MoC than sham mice (Figure 4(b), 
p < .05 vs sham mice and p < .05 vs TMEV-mice). 
Indeed, when we analyzed the expression of pro- 
inflammatory cytokine genes (Figure 4(b)), we 
found that the elevated expression of IL-1β and IL- 
6 in TMEV-mice (p < .001 and p < .05 vs sham, 
respectively) was significantly reduced by Vivomixx 
(p < .01 and p < .05 vs TMEV-mice, respectively). 
Conversely, expression of the IL-10 gene was pro-
moted by Vivomixx (p < .01 vs TMEV-mice), while 
IL-4 expression displayed a tendency toward 
enhancement. Intriguingly, the elevated TNF-α gene 
expression observed in TMEV-mice remained 
unchanged by the probiotic treatment (Figure 4(c)).
Peripheral immunological changes in the 
symptomatic chronic phase of TMEV-IDD associated 
with Vivomixx supplementation
The proportions of CD4+ and CD8+ T cells in the 
spleen of TMEV-mice were not significantly 
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Figure 2. Changes in gut microbiota population after Vivomixx treatment. Fecal pellets were collected freshly from each mouse before 
and after probiotic treatment. A) Stacked bar charts of the relative abundance of main bacterial communities, at genus level, present in 
the different experimental groups. Extended error bar plots, at phylum (b) and genus level (c), shows the differences in the mean 
proportions of bacterial taxa in TMEV mice before (black) and after treatment (green). Corrected p-values are shown on the right. D) 
Quantification of the plasma levels of acetate and butyrate. The data are presented as the means ± SEM: ***p < .001 vs. S; ##p < .01 vs 
T; n = 5 mice/group.
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affected by Vivomixx administration (Figure 5(a)), 
although more intense CD4+ fluorescence was 
evident in T cells from TMEV-mice and this was 
dampened when they received the probiotic (Figure 
Figure 3. Effect of Vivomixx treatment on the T and B cell populations in the CNS. A single cell leukocyte suspension was obtained from 
the brain and spinal cord. A, H) Representative flow cytometry plots of CD45+CD3+CD4+ T cells, CD45+CD3+CD8+ T cells (a), and 
B220+CD19+ B cells and CD5+CD1dhigh cells gated on B220+CD19+ B cells (h). B-D) Quantification of the change in the number of 
CD45+CD3+CD4+, CD45+CD3+CD8+ T cells and leukocytes relative to S mice E) Representative flow cytometry plots of CD39Foxp3 cells 
gated on CD45+CD3+CD4+ T cells. F-G) Percentage of Foxp3+CD39+ and Foxp3−CD39+ T cells gated on CD45+CD3+CD4+ T cells, 
respectively. The data represent the change relative to the S mice. I) Quantification of the change in the percentage of B220+CD19+ 
B cells relative to the S mice. J) Percentage of CD5+CD1dhigh cells gated on B220+CD19+ B cells in the CNS: Groups S, T (n = 10); groups 
SVx, TVx (n = 5); **p < .01 vs S; ***p < .001 vs. S; #p < .05 vs. T; ###p < .001 vs T.
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5(b)). Although the frequency of Treg cells was 
similar in TMEV-mice irrespective of their treat-
ment with Vivomixx, the percentage of 
Foxp3+CD39+ and Foxp3−CD39+ T cells was dra-
matically reduced in the spleen of TMEV-mice that 
received Vivomixx (p < .05 and p < .001 vs TMEV, 
respectively) (Figure 5(c)). By contrast, there were 
no significant changes in the proportion of B cells 
(Figure 5(d)) or in the abundance of Breg cells in 
the spleen of TMEV-mice receiving Vivomixx.
Figure 4. Vivomixx administration in the chronic phase of TMEV-IDD promotes anti-inflammatory responses in the spinal cord. A) 
Representative images of transversal spinal cord sections immunostained with Iba-1 to label microglia. Scale bar 100 μm. Below are 
higher magnification images (63x) of Iba-1 stained cells that indicate the changes in morphology. Scale bar 10 μm. Quantification of 
the area occupied by Iba-1 staining is also shown on the right. B) Representative images of GFAP (red) and Vimentin (green) staining in 
the spinal cord together the quantification of Vimentin-GFAP overlap through the Manders coefficient measure. C) qRT-PCR analysis of 
inflammatory markers (mIL-1β, mIL-6, mTNF-α, mIL-4 or mIL-10) in the spinal cord as assessed using the 2−ΔΔCt method. *p < .05 vs. S; 
**p < .01 vs. S; ***p < .001 vs. S; #p < .05 vs. T; ##p < .01 vs. T.
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Figure 5. Subtle changes in the peripheral immunological response after Vivomixx administration to TMEV-mice. A spleen cell 
suspension was stained to analyze the CD4, CD8, CD39+ Treg and Breg cell populations. a) Representative flow cytometry plots of 
CD45+CD3+CD4+ T cells and CD45+CD3+CD8+ T cells, along with their corresponding quantification. b) Histogram of fluorescence 
emitted by CD3+CD4+ spleen cells from representative mice in each experimental group. c) Flow cytometry plots of Foxp3+CD39+ Treg 
cells gated on CD45+CD3+CD4+ T cells, together with a quantification of the percentage of Foxp3+ T cells (gated on CD4+ T cells), 
Foxp3−CD39+ and Foxp3+CD39+ Treg cells. d) Representative flow cytometry images and quantification of the B220+CD19+ cells in the 
spleen, together with a normalized histogram and quantification of CD1d expression in B220+CD19+CD5+ gated cells. Groups. S, 
T (n = 10); groups SVx, TVx (n = 5); **p < .01 vs S; ***p < .001 vs. S; #p < .05 vs. T; ###p < .001 vs T.
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No significant variation was detected in the num-
ber of CD4+ T cells in the MLNs under the different 
conditions studied (Figure 6(a)). However, the 
release of IL-17 by Th17 polarized lymphocytes 
derived from TMEV-mice was stronger respect to 
sham mice (p < .05) (Figure 6(b)). By contrast, sig-
nificantly less IL-17 was produced by CD4+ T cells 
obtained from the MLNs of TMEV-mice that 
received Vivomixx (p < .05 vs TMEV-mice).
Discussion
In the last decade, evidence has emerged of 
a relationship between gut microbiota and MS, 
both in patients and in animal models.4,5,18,19 In 
addition, there is significant support for the gut 
microbiota playing a critical role in shaping the 
immune system.20–22 Several reports described, in 
EAE models, a therapeutic effect of multi-strain 
probiotics15 and specific bacterial strains like 
Bacteroides,9,10 Prevotella11 or Lactobacillus. 
However, the involved mechanisms for their bene-
fits seem to be different. For example, while 
L. paracasei DSM13434 and L. plantarum DSM 
15312 increased TGF-β1 in the blood, 
L. plantarum DSM 15313 enhanced blood levels 
of IL-27.12 Until date the only probiotic considered 
a kind of medical food is Vivomixx23.Here, we 
proved the efficacy of Vivomixx treatment in 
a model of progressive MS whereby oral 
administration of this probiotic, during the chronic 
phase improved the motor disability likely asso-
ciated to changes in gut microbiota.
Differences in the composition of the fecal 
microbiota at the genus level have been reported 
in a variety of studies on MS patients.4,5,18,19 In our 
study TMEV-mice showed changes in gut micro-
biota population compatible with MS disease like 
decreases of Prevotella, Bacteroides, Parabacteroides 
or Coprobacillus relative abundance or an increase 
of Anaerostipes.18,24,25 Vivomixx treatment tends to 
decrease Anaerostipes, Dorea, Oscillospira, 
Enterobacteraceae or Ruminococcus while 
Bacteroides, Odoribacter, Lactobacillus, or 
Sutterella were increased. These changes would be 
associated with the beneficial effects of probiotic 
treatment. For example, Dorea have been consid-
ered to be part of the healthy gut microbiota or 
patients on disease-modifying treatment show 
increased abundance of Sutterella and Prevotella.5
In the TMEV-IDD model we found that mice 
receiving oral Vivomixx had fewer CNS infiltrated 
leukocytes, particularly B cells, without significant 
changes in the proportion of CD4+ and CD8+ 
T cells, Treg cells, or Foxp3+CD39+ T cells. One 
of the pathways by which the commensal micro-
biome affects host immunity at distal sites is by 
regulating the activity of Treg cells through the 
ectonucleotidase CD39.10 Particularly, CD39+ cells 
have been associated with the suppression of 
Figure 6. Vivomixx affects the Th17 responses in the MLNs. CD4 T cells isolated from MLN were polarized to Th17 in culture. The 
expression of IL-17 was measured by ELISA, and the data represent the mean ± SEM of the change relative to the S or T mice from two 
experiments performed in triplicate: *p < .001 vs S; #p < .05 vs T.
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neuroinflammation by Bacteroides fragilis in the 
EAE model26 and its polysacharide A was not able 
to protect against EAE in CD39-deficient mice.10 
Here, TMEV infection decreased CD39 Treg cells 
population in the CNS, in accordance with our 
previous results27 and previous data from the per-
ipheral blood of MS patients.28 Unlike what we 
might expect, probiotic treatment did not reverse 
the decreased CD39+ Tregs suggesting that CD39 
activity is not the main pathway involved in the 
anti-inflammatory effects of Vivomixx. Indeed, our 
results are consistent with data from MS patients 
who did not show changes in the frequencies of 
CD4, CD8 or CD39+T cells following Vivomixx.17
It is known that in EAE, encephalitogenic T cells 
upregulate their CD4 cell surface expression follow-
ing antigen recognition and that this was associated 
with EAE development, for example after transfer 
to naïve animals.29 Therefore, although oral 
Vivomixx did not affect the frequency of CD4+ 
T cells, the fact that this probiotic restricted the 
surface expression of CD4 on T cells suggest its 
possible contribution to its beneficial effects in 
TMEV mice.
Recent reports show that gut microbiota and 
microbial products can directly regulate B-cell 
development, activation, and differentiation.30 In 
addition, the induction of Breg cells in an autoim-
mune context was seen to depend on a healthy 
microbiota.31 Notably, in our model of progressive 
MS, Vivomixx increased the frequency of Breg cells, 
unveiling a different mechanism of action to that 
exerted by other probiotics in EAE models where 
Treg cells have been specifically implicated.26,32 
Nonetheless, Bregs would be involved in the bene-
ficial effect of Vivomixx but functional studies are 
needed to be sure that these cells are working in an 
effective way. There are many crucial differences 
between EAE and the TMEV model. First, the 
TMEV ability to maintain the inflammation into 
the CNS compartment, with minor effects in the 
periphery unlike that observed in EAE. On this way, 
most of studies noticed the induction of IL-10 pro-
ducing Tregs in the periphery as the main mechan-
ism for EAE protection when mice received many 
probiotics as Lactobacilli12 or Prevotella Histicola.11 
The second possibility comes from the different 
strain of mice used in the models of MS. In EAE 
models that use SJL/L mice, like we used in the 
present study, the protective effects against EAE 
following Lactobacillus helveticus seems to involve 
decreased IL-6 and reduced Th-17 cells in the spinal 
cord, without changes in Tregs.14
Preclinical studies suggest that the microbiome 
plays a critical role in regulating microglial matura-
tion and function.33 Indeed, microglia from TMEV- 
infected mice administered Vivomixx undergo mor-
phological changes, which could reflect changes in 
their functional state, in accordance with the emer-
gent hypothesis that microglia may adopt distinct 
CNS region-specific phenotypes.34 In the spinal 
cord, the pro-inflammatory environment of TMEV- 
mice shifted to an anti-inflammatory profile follow-
ing Vivomixx supplementation.
In an attempt to find a mechanism that may 
explain the changes in the CNS of TMEV-mice 
that receive oral Vivomixx we assessed plasma acet-
ate and butyrate. On the whole, it seems that the 
reduction in bacteria producing SCFAs may be 
a common characteristic of MS patients.18 A high 
fiber diet or SCFA supplementation are reported to 
ameliorate EAE35 and, there is growing evidence 
supporting that circulating metabolites of the 
microbiota can influence CNS and immune cell 
activity,33 including microglial function.27,36 One 
of the most significant findings of the present 
study was the increased butyrate and acetate levels 
in the plasma of TMEV-mice that received 
Vivomixx which may contribute to the altered 
immune CNS responses and the improved motor 
activity. Indeed, several reports indicate the bene-
ficial effects of SCFA suppressing inflammation in 
the EAE model.35,37,38 Furthermore, a recent find-
ing shows that specific SCFAs exert an epigenetic 
modulation of Breg responses.39,40 Particularly, 
EAE mice that were subjected to the transference 
of Breg cells, expanded in vitro in presence of 
pentanoate, did not develop the classical symptoms. 
Furthermore, butyrate increased the levels of 
5-Hydroxyindole-3-acetic acid, a metabolite of ser-
otonine neurotransmitter which activates the aryl- 
hydrocarbon receptor (AhR), a newly discovered 
transcriptional marker for Breg function.41 Here, 
we speculate that Breg response as well as the 
reduction of IL17 production by Th17 mesenteric 
polarized cells may be associated with acetate and 
butyrate increments following Vivomixx adminis-
tration to TMEV-mice.
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Although, there is no clear evidence of 
a relationship between SCFA and Bregs at CNS 
level, astrocytes express AhR that, when activated 
limit CNS inflammation. In the EAE model the 
results by Quintana’s group42 suggest a link 
between metabolites derived from dietary trypto-
phan by the commensal gut bacteria and the activa-
tion of AhR signaling in astrocytes. It is worth 
noting that our understanding of the molecular 
pathways involved in the effects of probiotics and 
SCFAs on CNS inflammation, in MS and its animal 
models, is still very limited. This statement also 
includes microglial cells which are thought to be 
targeted by SCFAs,36 although their underlying 
mechanisms remain incomplete too. On this line, 
more recently, a new pathway in which microbial 
metabolites may limit the pathogenic activity of 
microglia and astrocytes has been identified.43 
Then, we would like to highlight the reduction of 
astrogliosis and microgliosis we found in Vivomixx 
treated-TMEV mice.
An important issue to consider is that MS disease 
modifying therapies may alter the microbiome 
directly. As an interesting example, the abundance 
of Prevotella was increased in MS patients treated 
with glatiramer acetate taking into account that MS 
reduced the frequency of these bacteria.44 
Furthermore, in a humanized transgenic EAE pre-
clinic model of MS, the combination of human 
Prevotella histicola and glatiramer acetate did not 
have a synergistic effect, but Prevotella was as effec-
tive as glatiramer in suppressing the disease.11
While dogma dictates that Firmicutes are 
responsible for butyrate and Bacteroidetes are 
responsible for acetate and propionate production, 
there is evidence for alternative pathways.45 There 
are non-canonical butyrate-producing pathways 
that use amino acids as primary substrates, includ-
ing the lysine, 4-aminiobutyrate, pathways. 
Considering metagenomic analysis of samples 
from healthy human patients from the Human 
Microbiome Project a significant overlap between 
the genes involved in the lysine and 4-aminobuty-
rate pathways and those expressed by members of 
the phylum Bacteroidetes was found for butyrate 
production. Then, it was predicted that these both 
pathways can contribute to the butyrogenic poten-
tial of Bacteroidetes.46 Because members of the 
Odoribacter genus dominated the lysine and 
4-aminobutyrate pathways, our finding about 
increased Odoribacter abundance would be asso-
ciated with the increased levels of butyrate in 
TMEV-mice treated with Vivomixx.
The subtle changes promoted by Vivomixx at 
spleen level are in accordance with the compart-
mentalization of inflammation that occurs in pro-
gressive MS, characterized by intrinsic CNS 
processes driven by resident cells like microglia 
and astrocytes. As such, the main immunological 
changes in the chronic phase of TMEV-IDD linked 
to the manipulation of the gut microbiota by oral 
Vivomixx happen within the CNS. Although pro-
biotics do not modify the host microbiome in 
a robust and persistent manner, they can influence 
gut immunity and homeostasis.47 Such effects were 
evident in the TMEV model through the CNS 
immune responses, microgliosis and astrogliosis, 
IL-17 production by ex vivo mesenteric CD4+ 
T cells, and more importantly, the severity of 
motor dysfunction.
Regarding probiotics as therapeutic agents, 
VSL#3 administered to a small number of RRMS 
patients leads to an anti-inflammatory peripheral 
immune response.17 It seems clear that both, dis-
ease promotion and amelioration may be induced 
by specific components of the gut microbiota that 
interact bi-directionally with the host immune sys-
tem. This concept implies that selective experimen-
tal strategies manipulating specific subsets of 
bacteria or balancing specific gut microbiota may 
be useful as a therapeutic approach in MS. Our 
findings may provide a starting point for further 
mechanistic studies that help to develop adjuvant 
treatments complementary to the available thera-
peutic options for progressive MS patients.
Materials and Methods
Animals and TMEV infection
TMEV-infected susceptible female SJL/J mice 
(Charles River) were maintained under conven-
tional controlled conditions. The right brain hemi-
sphere of 6–8 weeks-old mice was inoculated with 
2 × 106 plaque forming units (pfu) of the Daniel 
(DA) strain of TMEV). Sham control mice received 
the vehicle alone. Each experimental group was 
housed in different cages and in different isolated 
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racks in the same room. Each cage contained 5 mice 
subjected to the same treatment, receiving the same 
food and sterile water, and manipulated by the 
same person. All experiments were performed in 
strict accordance with EU (Directive 2010/63/EU) 
and Spanish regulations (Royal Decree 53/2013 
BOE n° 34 and “Comunidad de Madrid” decree: 
ES 280790000184). The Ethics Committee on 
Animal Experimentation at the Instituto Cajal 
approved all the procedures employed in this 
study (protocol number: 2013/03 CEEA-IC).
Treatments
TMEV-mice were orally gavaged with 3 × 108 cfu 
(100 μl) of Vivomixx for 70 to 85 days post infec-
tion (dpi) (TVx group; n = 10). Vivomixx, a multi- 
species probiotic is composed of Lactobacillus para-
casei DSM 24734, Lactobacillus plantarum DSM 
24730, Lactobacillus acidophilus DSM 24735, 
Lactobacillus delbruckeii subspecies bulgaricus 
DSM 24734, Bifidobacterium longum DSM 24736, 
Bifidobacterium infantis DSM 24737, 
Bifidobacterium breve 24732 and Streptococcus ther-
mophilus DSM 24731. Sham or TMEV-mice admi-
nistered the vehicle (S group, n = 10 or T group, 
n = 10, respectively) and Sham mice administered 
Vivomixx (SVx group, n = 5).
Evaluation of motor function
Mice were followed for the progression of demye-
linating disease by evaluating spontaneous motor 
activity on day 70 and 85 pi using an activity cage 
(Activity Monitor System Omnitech Electronics, 
Inc.; Colombus, OH, USA) and motor coordination 
by rotarod test as we previously described.48
Sample collection
Fecal samples freshly obtained from each mouse 
on day 70 and 85 pi were stored at −80°C. On day 
85 pi, spleen and MLN were removed from 
anesthetized mice (Dolethal; 50 mg/kg body 
weight) for flow cytometry and ex vivo CD4-T cell 
studies. Then, anesthetized mice were perfused 
transcardially with saline to obtain the brain and 
spinal cord for further FACS analysis.
Metabolite analysis
Blood samples in EDTA-treated BD vacutainer 
were centrifuged for 10 min at 1500 g in a refriger-
ated centrifuge within two hours of extraction and 
aliquots were stored at −20°C. Acetate and butyrate 
levels were assessed as described previously.27 
Validation of the method was carried out 
using13C-acetate and13C-butyrate standards. For 
both analytes the recoveries were above 90% and 
the precision, in terms of relative standard devia-
tion, was below 10%.
Ex vivo experiments on CD4 T cells
CD4+ T cells were isolated from the MLN using 
a commercial cell isolation kit and following the 
manufacturer’s instructions (Miltenyi, Biotec Inc). 
Cells from each animal were cultured and polarized 
to Th17 cells in RPMI supplemented with: 2-β 
Mercaptoethanol (50 μM); immobilized anti- 
mouse CD3ε; anti-mouse CD28; anti-mouse IFN- 
γ; anti-mouse IL-4 (all from BD biosciences); 
hTGF-β and recombinant murine IL-6 (from 
Peprotech); and recombinant murine IL-23 
(BioLegend). The cells were stimulated 3 days 
later for 5 hours with PMA (100 ng/ml) and iono-
mycin (500 ng/ml, both from Tocris Bioscience). 
The supernatants were collected and stored at −20° 
C for IL-17 measurement by solid phase sandwich 
ELISA using Quantikine kits (M1700; R&D systems 
Inc), according to the manufacturer’s instructions. 
The assay’s sensitivity was 5 pg/ml.
Tissue processing and immunohistochemistry
Anesthetized mice were perfused transcardially 
with saline and the spinal cord processed as pre-
viously described.48 Microglia were labeled with 
a primary antibody against Iba-1 (ionized calcium 
binding adaptor molecule 1, 1:1,000: Wako 
Chemical Pure Industry), while reactive astrogliosis 
was assessed by GFAP (1:2000: Sigma) and 
Vimentin (1:1000: Sigma) labeling. Five spinal 
cord sections were examined per animal and at 
least three mice per group were used to quantify 
the immunostained area using ImageJ software 
(NIH, Bethesda). The white matter area in the 
ventral and lateral horns was analyzed by 
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immunofluorescence on a Leica TC SP5 confocal 
microscope. Representative images of the surface of 
a single microglial cell were obtained with Imaris 
software. Astroglial activation defined as the 
amount of Vimentin relative to the GFAP staining 
(Vimentin-GFAP overlapping) was analyzed using 
the Manders overlap coefficient (MoC) that quan-
tifies the degree of co-localization of the two 
fluorophores.
RNA extraction, reverse transcription and RT-PCR
Total RNA from the cervical spinal cord was 
extracted and then transcribed into cDNA as we 
previously described.49 Real-time PCR (RT-PCR) 
was performed with SYBR® and the following oli-
gonucleotide primers mIL-1β, forward 5ʹ-TGG 
TGT GTG ACG TTC CCA TT-3ʹ, reverse 5ʹ-TCC 
ATT GAG GTG GAG AGC TTT C-3ʹ; mTNF-α, 
forward 5ʹ-AGA GGC ACT CCC CCA AAA GA-3ʹ, 
reverse 5ʹ-CGA TCA CCC CGA AGT TCA GT-3ʹ; 
mIL-4, forward, 5ʹ-CCACGGATGCGACAAAA 
ATC-3ʹ, reverse 5ʹ-GACGTTTGGCACATCCA 
TCTC-3ʹ; mIL-10, forward 5ʹ-TGA ATT CCC 
TGG GTG AGA AGC TGA-3ʹ, reverse 5ʹ-TGG 
CCT TGT AGA CAC CTT GGT CTT-3ʹ; mIL-6, 
forward 5ʹ-TCC AGA AAC CGC TAT GAA GTT 
C-3ʹ, reverse 5ʹ-CAC CAG CAT CAG TCC CAA 
GA-3ʹ; and mRps29 forward 5ʹ-GCC GCG TCT 
GCT CCA A-3ʹ, reverse 5ʹ-ACA TGT TCA GCC 
CGT ATT TGC-3ʹ. PCR amplification were 
initiated incubating at 50°C for 2 min and 95°C 
for 10 min, and amplification was performed over 
40 cycles at 95°C for 15 s and 60°C for 1 min. The 
cDNA samples were analyzed in triplicate on an 
Applied Biosystems PRISM 7500 Sequence detec-
tion system, normalizing the mRNA expression to 
the Rps29 gene in each sample and quantifying gene 
expression by the 2−ΔΔCt method. The results are 
expressed relative to the Sham mice for each time 
point.
Flow cytometry antibodies
A CNS or spleen leukocyte suspension was 
obtained as described previously.49 Freshly iso-
lated cells (106) were incubated with an anti- 
mouse CD16/CD32 FC (eBioscience) and labeled 
with anti-mouse antibodies: PE anti-CD25; PE 
anti-CD3; PerCP-Cy5.5-conjugated anti-CD45; 
PerCP-Cy5.5-conjugated anti-B220; PE-Cy7- 
conjugated anti-CD39; PE-Cy7-conjugated anti- 
CD8a; PE-Cy7-conjugated anti-CD19; APC anti- 
CD3; APC-Cy7-conjugated anti-CD4; APC-Cy7- 
conjugated anti-CD11b (all from BD 
Pharmingen); APC anti-CD3; and PE-Cy7- 
conjugated anti-CD39 (both from eBioscience). 
To detect Foxp3, the cells were suspended in the 
fixation/permeabilization buffer and stained with 
a PE anti-Foxp3 antibody (BD Pharmingen). 
Cell viability was assessed with the LIVE/DEAD 
Fixable Green Dead Cell Stain Kit or LIVE/ 
DEAD Fixable Red Dead Cell Stain Kit (Life 
Technologies Corporation). At least 10,000 
events were acquired in each experiment on 
a FACSaria flow cytometer (BD Biosciences) 
and the data were analyzed using FlowJo soft-
ware (v.10; Tree Star).
16S rRNA analysis of the microbial community
Fecal DNA was isolated using the QIAamp DNA 
Stool Mini Kit (Qiagen; cat. no. 51504) and follow-
ing the stool pathogen detection protocol. DNA 
was extracted following the manufacturer’s 
instructions with the modifications described 
previously,27 and the quality of the reads was ana-
lyzed with FastQC software (http://www.bioinfor 
matics.babraham.ac.uk/projects/fastqc/). The 
microbiome analysis of the paired-end reads was 
performed using the QIIME2 v2018.8 software 
(Qualitative Insights into Microbial Ecology)50 
and the sequences were grouped as “sequence var-
iants” (SVs), equivalent to the 100% Operational 
Taxonomic Units (OTUs). Representative 
sequences from each cluster were queried against 
the GreenGenes database (version 13_8) to obtain 
taxonomic assignments at a 97% sequence identity 
using BLAST. These representative sequences 
were then used for phylogenetic analysis and for 
diversity calculations.
Statistical analysis
The data were expressed as the mean ± standard 
error or the mean (SEM) and they were analyzed 
using GraphPath Prism5 Software. One-Way 
ANOVA followed by the Bonferroni post hoc 
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test were used to determine the statistical sig-
nificance. For non-parametric analyzes, 
a Kruskall-Wallis and Mann-Whitney U test 
were applied.
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